NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction

SANTA CLARA, Calif., April 7, 2011 /PRNewswire/ — PR
Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac
diagnostic technology provider, announced today that the Company
has been invited by the American Diabetes Association (ADA) to
present the results of a key study showing that NewCardio’s urgent
care solution, my3KG™, had substantially greater accuracy
than expert cardiologists’ interpretation of standard 12-lead ECG
(12L ECG) in diagnosing Acute Myocardial Infarction (AMI) in
diabetic patients.  The presentation will be made at the 71st
Annual ADA Scientific Sessions to be held in San Diego, CA, June
24-28, 2011.  In addition, the ADA has selected this
presentation to be showcased in the Guided Audio Poster Tour, which
features expert moderators that share their perspectives with
attendees, highlighting novel and important developments in the
field.

Dr. Ihor Gussak, MD, PhD, NewCardio’s Chief Medical Officer,
commented, “We are delighted to present our study results at this
important gathering of diabetes experts, and particularly pleased
that the ADA program committee chose to feature our presentation in
a moderated poster session.  Accurate and timely AMI diagnosis
is a matter of great concern for diabetologists, and we believe our
results show that my3KG can play a major role in solving it.
 The moderated poster session provides the opportunity to
present our results directly to leading diabetes experts, and have
one-on-one interactions that will allow us to discuss and explain
the importance of our results in detail.”

Study Background and Results

Diabetics with AMI represent a very large and growing patient
group, and currently affect over 10% of adults in the U.S.
 Moreover, the incidence of AMI is two to four times greater
in diabetics than in the general population, according to ADA and
American Heart Association statistics.  Accurate and timely
diagnosis of AMI is notorious

‘/>”/>

SOURCE